Abstract
Background To analyse the impact of the Novel Coronavirus Pneumonia (NCP) outbreak on the facemask shortage in China and provide insight into the development of emergency plans for future infectious disease outbreaks.
Methods Policy review using government websites and shortage analysis using mathematical modelling based on data obtained from the National Health Commission (NHC), the Ministry of Industry and Information Technology (MIIT), and the Center for Disease Control and Prevention (CDC) of the People’s Republic of China.
Findings Supplies of facemasks in the whole of China would have been sufficient for both the healthcare workers and the general population if the NCP outbreak only occurred in Hubei province. However, if the outbreak occurred in both Hubei and Guangdong provinces, facemask supplies in the whole of China could last for 34 days if no alternative public health intervention was introduced. There would be a shortage of 480 million facemasks by mid-February 2020. If the outbreak occurred in the whole of China, facemask supplies could only last for 16 days and the shortage would considerably worsen, with a shortage of 11·5 billion facemasks by mid-February 2020.
Interpretation In light of the novel coronavirus outbreak in China, insufficient medical resources (e.g., shortage of facemasks) can considerably compromise the efficacy of public health measures. An effective public health intervention should also consider the adequacy and affordability of existing medical resources. Global collaboration should be strengthened to prevent the development of a global pandemic from a regional epidemic via easing the medical resources crisis in the affected countries.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available on request from the authors
